Atlas of Genetics and Cytogenetics in Oncology and Haematology
| CASE REPORTS in
HAEMATOLOGY (Paper co-edited with the European LeukemiaNet) |
| A new case of t(16;21)(q24;q22) in a secondary AML-M2 following breast cancer therapy |
| Written | 2005-08 | Hélène Bruyère, Wilson Yeung, Peter Tsang |
| Department of Pathology and Laboratory Medicine, Vancouver General Hospital, UBC, Canada, Helene.Bruyere@vch.ca and Division of Hematology, Vancouver General Hospital, UBC, Canada |
| Clinics |
| Age and sex : | 61 year(s) old female patient. |
| Previous History : | no preleukemia |
| no inborn condition of note |
| Organomegaly : no hepatomegaly ; no splenomegaly ; no enlarged lymph nodes ; no central nervous system involvement |
| Blood |
| WBC : 2.4 x 109/L ; Hb : 10.7 g/dL ; platelets : 48 x 109/L; blasts : 2 % . |
| Bone marrow : Neutrophils 0.05 ; Band cells 0.05 ; Metamyelocytes 0.13 ; Myelocytes 0.02 ; Promyelocytes 0.02 ; Blasts 0.51 ; Late normoblasts 0.13 ; Plasma cells 0.01 ; Lymphocytes 0.05 ; Monocytes 0.01 ; Eosinophils 0.02 |
| Cyto pathology classification |
| Cytology : AML-M2 |
| Immunophenotype : Positive for HLA-DR, CD34, CD117, CD13, CD33, MPO, CD56 and CD19 ; Partial Tdt ; Negative for CD7 |
| Precise diagnosis : Hypoplastic AML, therapy related |
| Survival |
| Date of diagnosis: 04-2005 |
| Treatment : Three cycles of AraC and Danuribicin ; Related bone marrow transplantation planned for September 2005 |
| Complete remission : None |
| Status : Alive 07-2005 |
| Survival : 3 month(s) |
| Karyotype |
| Sample : Bone marrow ; culture time : 24 h ; banding : GTG |
| Results : 47,XX,+8,t(16;21)(q24;q22)[13]/46,XX[3] |
 |
| Partial karyotype showing the t(16;21) and a +8 |
| Comments |
| The t(16;21)(q24;q22) is mainly found in t-MDS/t-AML (14/16 cases (1-10)), following breast cancer therapy (five cases (7,8,10)), lymphoma (four cases), Hodgkin's disease, lung and oviductal cancers and AML-M3 (one case each). Trisomy 8, the secondary change found in the current case, is also reported in most if not all patients with previous breast cancer (7,8,10). To note, three out of five patients had lymphoid positive antigenes (5,7, current case). All of the nine patients whose treatments were reported (3-9), plus the current case, were treated with a combination of alkylating agents and topoisomerase II inhibitors, +/- radiotherapy. |
| Internal links |
| Atlas Card | t(16;21)(q24;q22) |
| Case Report | A case of trisomy 8 and loss of the Y-chromosome as secondary aberrations in a ten year old boy with de novo AML FAB M2 and t(16;21)(q24;q22) |
| Bibliography |
| Cytogenetics of childhood acute nonlymphocytic leukemia. |
| Raimondi SC, Kalwinsky DK, Hayashi Y, Behm FG, Mirro JJr, Williams DL. |
| Cancer Genet Cytogenet 1989; 40: 13-27. |
| PMID 2758395 |
| Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with hematopoietic malignancies. |
| Nylund SJ, Ruutu T, Saarinen S, Knuutila S. |
| Br j Hematol 1994; 88: 778-783. |
| PMID 7819102 |
| Clonal Kryotypic hematopoietic cell abnormalities occuring after autologous bone marrow transplantation for Hodgkin's disease and non-hodgkin's disease. |
| Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SJ. |
| Blood 1994; 84(3): 957-963. |
| PMID 8043877 |
| Secondary acute myeloblastic leukemia with t(16;21) involving the AML1 gene. |
| Berger R, Le Coniat M, Romana SP, Jonveaux P. |
| Hematol Cell Ther 1996; 38: 183-186. |
| PMID 8932000 |
| A recurrent translocation, t(16;21)(q24;q22), associated with acute myelogenous leukemia: identification by fluorescence in situ hybridization. |
| Shimada M, Ohtsuka E, Shimizu T, Matsumoto T, Matsushita K, Tanimoto F, Kajii T. |
| Cancer Genet Cytogenet 1997; 96: 102-105. |
| PMID 9216714 |
| A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA_topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide. |
| Takeda K, Shinohara K, Kameda N, Ariyoshi K. |
| Int j Hematol 1998; 67: 179-186. |
| PMID 9631585 |
| AML1-MTG16 fusion gene in therapy-related acute leukemia with t(16;21)(q24;q22): two new cases. |
| Salomon-Nguyen F, Busson-Le Coniat M, Lafage Pochitaloff M, Mozziconacci J, Berger R, Bernard OA. |
| Leuk 2000; 14: 1704-1710. |
| PMID 10995019 |
| AML1/MTG16 fusion gene from a t(16;21)(q24;q22) translocation in treatment-induced leukemia after breast cancer. |
| La Starza R, Sambani C, Crescenzi B, Matteucci C, Martelli MF, Mecucci C. |
| Haematologica 2001; 86(2): 212-213. |
| PMID 11224496 |
| A pediatric case of secondary leukamia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene. |
| Kondoh K, Nakata Y, Furuta T, Hosoda F, Gamou T, Kurosawa Y, Kinoshita A, Ohki M, Tomita Y, Mori T. |
| Leuk Lymph 2002; 43(2): 415-420. |
| PMID 11999578 |
| 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. |
| Slovak ML, Bedell V, Popplewell L, Arber DA, Schoch C, Slater R. |
| Genes Chrom cancer 2002; 33: 379-394 |
| PMID 11921272 |
| Citation |
| This paper should be referenced as such : |
| Free journal version : [ pdf ] [ DOI ] |
| On line version : http://AtlasGeneticsOncology.org/Reports/1621BruyereID100013.html |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Wed Nov 13 22:51:57 CET 2019 |
For comments and suggestions or contributions, please contact us